CD274 and head and neck squamous cell carcinoma: Based on these results, pembrolizumab received Food and Drug Administration (FDA) approval as a first-line treatment for R/M HNSCC in patients with PD-L1 CPS ≥ 1 (monotherapy) and CPS < 1 (in combination with chemotherapy) [101,105].